OnabotulinumtoxinA for chronic migraine: a critical appraisal

References

• SteinerTJStovnerLJBirbeckGLMigraine the 7th disablerJ Headache Pain201314123566305
   PubMed Web of Science ®Google Scholar
• SteinerTJScherAIStewartWFKolodnerKLibermanJLiptonRBThe prevalence and disability burden of adult migraine in England and their relationship to age, gender and ethnicityCephalalgia20032351952712950377
   PubMed Web of Science ®Google Scholar
• ClarkeCEMacMillanLSondhiSWellsNEEconomic and social impact of migraineQ J Med1996897784
   Google Scholar
• StovnerLJAndreeCImpact of headache in Europe: a review for the Eurolight projectJ Headache Pain2008913914618418547
   PubMed Web of Science ®Google Scholar
• NatoliJLManackADeanBGlobal prevalence of chronic migraine: a systematic reviewCephalalgia20103059960919614702
   PubMed Web of Science ®Google Scholar
• BigalMEThe paradoxical effects of analgesics and the development of chronic migraineArq Neuropsiquiatr201169354455121755137
   PubMed Web of Science ®Google Scholar
• IHSThe international classification of headache disorders: 3rd edition (beta version)Cephalalgia201333962980823771276
   PubMed Web of Science ®Google Scholar
• BigalMESerranoDReedDMLiptonRBChronic migraine in the population: burden, diagnosis, and satisfaction with treatmentNeurology20087155956618711108
   PubMed Web of Science ®Google Scholar
• StokesMBeckerWJLiptonRBCost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS)Headache2011511058107721762134
   PubMed Web of Science ®Google Scholar
• BlumenfeldAMVaronSFWilcoxTKDisability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS)Cephalalgia20113130131520813784
   PubMed Web of Science ®Google Scholar
• GooriahRAhmedFTherapeutics uses of botulinum toxinJ Clin Toxicol20155225
   Google Scholar
• BinderWJBlitzerABrinMFTreatment of hyperfunctional lines of the face with botulinum toxin ADermatol Surg199824119812059834739
   PubMed Web of Science ®Google Scholar
• NICE technology appraisal guidance 260. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine2012 Available from: http://publications.nice.org.uk/botulinum-toxin-type-a-for-the-prevention-ofheadaches-n-adults-with-chronic-migraine-ta260
   Google Scholar
• ScherAIStewartWFLibermanJLiptonRBPrevalence of frequent headache in a population sampleHeadache199838749750615613165
   PubMed Web of Science ®Google Scholar
• ScherAStewartWRicciJLiptonRFactors associated with the onset and remission of chronic daily headache in a population-based studyPain20031061818914581114
   PubMed Web of Science ®Google Scholar
• ChoSJChuMKRisk factors for chronic daily headaches or chronic migraineCurr Pain Headache Rep20151946525416458
   PubMed Web of Science ®Google Scholar
• ChenYCTangCHNgKWangSJComorbidity profiles of chronic migraine sufferers in a national database in TaiwanJ Headache Pain201213431131922527034
   PubMed Web of Science ®Google Scholar
• BigalMELiptonRBObesity is a risk factor for transformed migraine but not chronic tension-type headacheNeurology200667225225716864817
   PubMed Web of Science ®Google Scholar
• BigalMERapoportAMSheftellFDTepperSJLiptonRBTransformed migraine and medication overuse in a tertiary headache centre: clinical characteristics and treatment outcomesCephalalgia20042448349015154858
   PubMed Web of Science ®Google Scholar
• GoadsbyPJIs medication-overuse headache a distinct biological entity?Nat Clin Pract Neurol2006240116932591
   PubMedGoogle Scholar
• StarlingAJHoffman-SnyderCHalkerRBRisk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topicNeurologist201117529729921881477
   PubMed Web of Science ®Google Scholar
• LauritzenMPathophysiology of the migraine aura. The spreading depression theoryBrain1994117pt 11992107908596
   PubMed Web of Science ®Google Scholar
• AyataCCortical spreading depression triggers migraine attack: proHeadache20105072573020456160
   PubMed Web of Science ®Google Scholar
• OlesenJBursteinRAshinaMTfelt-HansenPOrigin of pain in migraine: evidence for peripheral sensitisationLancet Neurol2009867969019539239
   PubMed Web of Science ®Google Scholar
• LevyDMigraine pain and nociceptor activation – where do we stand?Headache20105090991620546325
   PubMed Web of Science ®Google Scholar
• GoadsbyPJCharbitARAndreouAPAkermanSHollandPRNeurobiology of migraineNeuroscience200916132734119303917
   PubMed Web of Science ®Google Scholar
• MoultonEABursteinRTullySHargreavesRBecerraLBorsookDInterictal dysfunction of a brainstem descending modulatory center in migraine patientsPLoS One20083e379919030105
   PubMed Web of Science ®Google Scholar
• SchwedtTJLarson-PriorLCoalsonRSAllodynia and descending pain modulation in migraine: a resting state functional connectivity analysisPain Med20141515416524165094
   PubMed Web of Science ®Google Scholar
• BursteinRZhangXLevyDAokiKRBrinMFSelective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other painsCephalalgia20143485386924694964
   PubMed Web of Science ®Google Scholar
• MathewNTPathophysiology of chronic migraine and mode of action of preventive medicationsHeadache201151849221770930
   PubMed Web of Science ®Google Scholar
• MathewNTKailasamJSeifertTClinical recognition of allodynia in migraineNeurology20046384885215365135
   PubMed Web of Science ®Google Scholar
• LouterMABoskerJEvan OosterhoutWPCutaneous allodynia as a predictor of migraine chronificationBrain20131363489349624080152
   PubMed Web of Science ®Google Scholar
• AuroraSKKulthiaABarrodalePMMechanism of chronic migraineCurr Pain Headache Rep201115576321197624
   PubMed Web of Science ®Google Scholar
• AuroraSKIs chronic migraine one end of a spectrum of migraine or a separate entity?Cephalalgia20092959760519228150
   PubMed Web of Science ®Google Scholar
• AuroraSKSpectrum of illness: understanding biological patterns and relationships in chronic migraineNeurology200972suppl 5S8S1319188565
   PubMed Web of Science ®Google Scholar
• AuroraSKBorrodalePMTiptonRLKhodavirdiABrainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studiesHeadache200747996100317635590
   PubMed Web of Science ®Google Scholar
• BernsteinCBursteinRSensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiologyJ Clin Neurol201282899922787491
   PubMed Web of Science ®Google Scholar
• CharlesACBacaSMCortical spreading depression and migraineNat Rev Neurol2013963764424042483
   PubMed Web of Science ®Google Scholar
• MesslingerKHaneschUBaumgartelMTrostBSchmidtRFInnervation of the dura mater encephali of cat and rat: ultrastructure and calcitonin gene-related peptide-like and substance P-like immunoreactivityAnat Embryol1993188213219
   Google Scholar
• MesslingerKFischerMJLennerzJKNeuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraineKeio J Med2011603828921979827
   PubMedGoogle Scholar
• Cernuda-MorollonELarrosaDRamonCVegaJMartinez-CamblorPPascualJInterictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraineNeurology2013811191119623975872
   PubMed Web of Science ®Google Scholar
• Cernuda-MorollonEMartinez-CamblorPAlvarezRLarrosaDRamonCPascualJIncreased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraineCephalalgia20153531031624847167
   PubMed Web of Science ®Google Scholar
• KostrzewaRSegura-AguilarJBotulinum neurotoxin: evolution from poison, to research tool – onto medicinal therapeutic and future pharmaceutical panaceaNeurotox Res20071227529018201955
   PubMed Web of Science ®Google Scholar
• SchantzEJJohnsonEAProperties and use of botulinum toxin and other microbial neurotoxins in medicineMicrobiol Rev199256180991579114
   PubMedGoogle Scholar
• RamachandranRYakshTLTherapeutic use of botulinum toxin in migraine: mechanisms of actionBr J Pharmacol2014171184177419224819339
   PubMed Web of Science ®Google Scholar
• DongMYehFTeppWHSV2 is the protein receptor for botulinum neurotoxin AScience200631259259616543415
   PubMed Web of Science ®Google Scholar
• FuZChenCBarbieriJTKimJJBaldwinMRGlycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype FBiochemistry2009485631564119476346
   PubMed Web of Science ®Google Scholar
• PengLBerntssonRPTeppWHBotulinum neurotoxin D-C uses synaptotagmin I/II as receptors and human synaptotagmin II is not an effective receptor for type B, D-C, and G toxinsJ Cell Sci20121253233324222454523
   PubMed Web of Science ®Google Scholar
• BrungerATRummelAReceptor and substrate interactions of clostridial neurotoxinsToxicon20095455056019268493
   PubMed Web of Science ®Google Scholar
• RisseladaHJGrubmullerHHow SNARE molecules mediate membrane fusion: recent insights from molecular simulationsCurr Opin Struct Biol20122218719622365575
   PubMed Web of Science ®Google Scholar
• RossettoOMontecuccoCPresynaptic neurotoxins with enzymatic activitiesHandb Exp Pharmacol200818412917018064414
   PubMedGoogle Scholar
• RummelAKarnathTHenkeTBigalkeHBinzTSynaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin GJ Biol Chem2004279308653087015123599
   PubMed Web of Science ®Google Scholar
• BarnesMBotulinum toxin – mechanisms of action and clinical use in spasticityJ Rehabil Med200341565912817658
   PubMedGoogle Scholar
• dePaivaAMeunierFAMolgóJAokiKRDollyJOFunctional repair of motor endplates after botulinum neurotoxin A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminalsProc Natl Acad Sci U S A1999963200320510077661
   PubMed Web of Science ®Google Scholar
• AokiKRFrancisJUpdates on the antinociceptive mechanism hypothesis of botulinum toxin AParkinsonism Relat Disord201117suppl 1S28S3321999893
   PubMed Web of Science ®Google Scholar
• DurhamPLCadyRInsights into the mechanism of onabotulinumtoxinA in chronic migraineHeadache201151101573157722082429
   PubMed Web of Science ®Google Scholar
• AokiKREvidence for antinociceptive activity of botulinum toxin type A in pain managementHeadache200343suppl 1S9S1512887389
   PubMed Web of Science ®Google Scholar
• DollyOSynaptic transmission: inhibition of neurotransmitter release by botulinum toxinsHeadache200343suppl 1S16S2412887390
   PubMed Web of Science ®Google Scholar
• Cernuda-MorollonERamonCMartinez-CamblorPSerrano-PertierraELarrosaDPascualJOnabotulinumtoxinA decreases interictal CGRP plasma levels in chronic migraine patientsPain2015156582082425735000
   PubMed Web of Science ®Google Scholar
• MatakIBach-RojeckyLFilipovicBLackovicZBehavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin ANeuroscience201118620120721539899
   PubMed Web of Science ®Google Scholar
• BinderWJBrinMFBlitzerASchoenrockLDPogodaJMBotulinum toxin type A (Botox) for treatment of migraine headaches: an open-label studyOtolaryngol Head Neck Surg200012366967611112955
   PubMed Web of Science ®Google Scholar
• SilbersteinSMathewNSaperJJenkinsSBotulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research GroupHeadache200040644545010849039
   PubMed Web of Science ®Google Scholar
• SchmittWJSloweyEFraviNWeberSBurgunderJMEffect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trialHeadache200141765866411554953
   PubMed Web of Science ®Google Scholar
• RollnikJDTannebergerOSchubertMSchneiderUDenglerRTreatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled studyHeadache200040430030510759934
   PubMed Web of Science ®Google Scholar
• RollnikJDKarstMFinkMDenglerRBotulinum toxin type A and EMG: a key to the understanding of chronic tension-type headaches?Headache2001411098598911903527
   PubMed Web of Science ®Google Scholar
• OndoWGVuongKDDermanHSBotulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design studyCephalalgia2004241606514687015
   PubMed Web of Science ®Google Scholar
• MathewNTFrishbergBMGawelMBOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trialHeadache200545429330715836565
   PubMed Web of Science ®Google Scholar
• SilbersteinSDStarkSRLucasSMBoNTA-039 Study GroupBotulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trialMayo Clin Proc20058091126113716178492
   PubMed Web of Science ®Google Scholar
• SilbersteinSDGöbelHJensenRBotulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group studyCephalalgia20062679080016776693
   PubMed Web of Science ®Google Scholar
• EversSOlesenJBotulinum toxin in headache treatment: the end of the roadCephalalgia20062676977116776690
   PubMed Web of Science ®Google Scholar
• FreitagFGDiamondSDiamondMUrbanGBotulinum toxin type A in the treatment of chronic migraine without medication overuseHeadache200848220120918042229
   PubMed Web of Science ®Google Scholar
• AuroraSDodickDTurkelCOnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia201030779380320647170
   PubMed Web of Science ®Google Scholar
• DienerHCDodickDWAuroraSKPREEMPT 2 Chronic Migraine Study GroupOnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialCephalalgia201030780481420647171
   PubMed Web of Science ®Google Scholar
• DodickDWTurkelCCDeGryseREPREEMPT Chronic Migraine Study GroupOnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical programHeadache201050692193620487038
   PubMed Web of Science ®Google Scholar
• AuroraSKWinnerPFreemanMCOnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical programHeadache2011511358137321883197
   PubMed Web of Science ®Google Scholar
• SilbersteinSTfelt-HansenPDodickDWTask Force of the International Headache Society Clinical Trials SubcommitteeGuidelines for controlled trials of prophylactic treatment of chronic migraine in adultsCephalagia200828484495
   PubMed Web of Science ®Google Scholar
• Tfelt-HansenPPascualJRamadanNInternational Headache Society Clinical Trials SubcommitteeGuidelines for controlled trials of drugs in migraine: third edition. A guide for investigatorsCephalalgia20123263822384463
   PubMed Web of Science ®Google Scholar
• SchwedtTJHentzJGDodickDWFactors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraineCephalalgia20072752853417459081
   PubMed Web of Science ®Google Scholar
• ManackATurkelCSilbersteinSThe evolution of chronic migraine: classification and nomenclatureHeadache2009491206121319438732
   PubMed Web of Science ®Google Scholar
• DienerHCSchornCFBingelUDodickDWThe importance of placebo in headache researchCephalalgia2008281003101118727647
   PubMed Web of Science ®Google Scholar
• GeraudGOlesenJPfaffenrathVComparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial designCephalalgia200020303810817444
   PubMed Web of Science ®Google Scholar
• MathewNTJaffriSFA double-blind comparison of onabotulinumtoxina (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot studyHeadache2009291466147819912346
   PubMedGoogle Scholar
• CadyRKSchreiberCPPorterJABlumenfeldAMFarmerKUA multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraineHeadache2011511213221070228
   PubMed Web of Science ®Google Scholar
• MagalhaesEMenezesCCardealMMeloABotulinum toxin type A versus amitriptyline for the treatment of chronic daily migraineClin Neurol Neurosurg2010112646346620399553
   PubMed Web of Science ®Google Scholar
• AuroraSKDodickDWDienerHCOnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical programActa Neurol Scand20141291617024107267
   PubMed Web of Science ®Google Scholar
• RothrockJFBloudekLMHouleTTAndress-RothrockDVaronSFReal-world economic impact of onabotulinumtoxinA in patients with chronic migraineHeadache2014541565157325298117
   PubMed Web of Science ®Google Scholar
• BattyAJHansenRNBloudekLMThe cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UKJ Med Econ201316787788723647483
   PubMedGoogle Scholar
• KhalilMZafarHAhmedFHull prospective analysis of onabotulinumtoxinA (Botox) in the treatment of chronic migraine; real-life data in 359 patients: an update4th European Headache Migraine Trust International Congress2014Copenhagen Abstract
   Google Scholar
• KhalilMZafarHQuarshieVAhmedFProspective analysis of the use of onabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UKJ Headache Pain2014155425178393
   PubMed Web of Science ®Google Scholar
• ZafarHKhalilMAhmedFOnabotulinumtoxinA (Botox) in the prevention of chronic migraine: comparing NICE criteria versus Hull criteria for evaluating responder rates4th European Headache Migraine Trust International Congress2014Copenhagen Abstract
   Google Scholar
• ZafarHKhalilMAhmedFHow long to continue Botox in Chronic Migraine patients? A two year follow up of 85 patients treated in Hull, UK4th European Headache Migraine Trust International Congress2014Copenhagen Abstract
   Google Scholar
• RothrockJKScanlonCWeibeltSOnabotulinumtoxinA for the treatment of chronic migraine: long-term outcomeAmerican Headache Association Meeting2011Washington DC, USA Abstract
   Google Scholar